Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00007020 |
Recruitment Status
:
Completed
First Posted
: December 7, 2000
Last Update Posted
: May 6, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OBJECTIVES:
I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism
II. To assess the safety and tolerability of cholic acid
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infantile Refsum's Disease Zellweger Syndrome Adrenoleukodystrophy Peroxisomal Disorders Cholestasis | Drug: Cholic Acids | Phase 3 |
Investigational Plan:
A Phase III, open label, single arm, nonrandomized, non-comparative, compassionate treatment study of cholic acid in the treatment of defects of bile acid metabolism.
The study was begun with a single study site at Cincinnati Children's Hospital Medical Center (CCHMC), but in 2005 was expanded so that compassionate treatment could be provided to additional patients who had been identified with inborn errors of bile metabolism through the center's screening/diagnostic program.
Patients who were screened were contacted and evaluated with respect to the inclusion/exclusion criteria. Signed informed consent by the patient and/or parents/legal guardian was obtained as soon as it is confirmed that the patient met inclusion/exclusion criteria and the parents/guardian would agree for the child to participate in the study.
The primary interventions for the study were:
- Administration of study drug.
- Collection of baseline physical exam, vital signs, blood and urine samples for laboratory tests.
- Collection of periodic physical exam, vital signs, blood and urine samples for laboratory tests during the period of administration of the study drug.
- Collection of any adverse event information.
Time and Events Schedule:
Baseline:
- Confirm eligibility
- Obtain written informed consent from patient and/or parents/legal guardian
-
Collect demographic data and disease and medication history, including family history
Baseline and Ongoing:
- Obtain body weight
- Record adverse events
- Obtain blood and urine samples for laboratory tests
- Initiate study drug therapy & monitor study drug therapy and adjust dose as needed
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 79 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism." This Study Was Previously Registered by the NCRR and Identified as NCRR-M01RR08084-0009 |
Study Start Date : | January 1992 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | December 2009 |

Arm | Intervention/treatment |
---|---|
Cholic Acid |
Drug: Cholic Acids
10-15 mg/kg body weight/day taken orally.
Other Names:
|
- Determination of changes in synthesis of atypical bile acids in urine by mass spectrometry (FAB MS) [ Time Frame: 12 months ]
- Change in Liver Function Test (serum transaminases) [ Time Frame: Standard of Care ]
- Change in Liver Histology (for patients in whom biopsy was performed) [ Time Frame: Standard of Care ]
- Safety Assessments (Incidence and Severity of Adverse Events) [ Time Frame: Each visit as standard of care ]
- Height and Weight [ Time Frame: Standard of Care ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Clinical or biochemical evidence of liver disease, unexplained fat-soluble vitamin malabsorption, or peroxisomal dysfunction that compromises bile acid biosynthesis
Inclusion criteria for enrollment were:
- Infants < age 3 months
- Children presenting for evaluation of cholestasis defined as a conjugated bilirubin > 2mg/dl or increased serum bile acids
- Older subjects of any age with cholestatic liver disease if urine screens suggested that they had inborn errors of bile acid metabolism
- Confirmation of a diagnosis of an inborn error of bile acid synthesis based upon urine analysis by FAB-MS to determine whether specific abnormalities in bile acid synthesis are indicated
- The patient and/or parent/legal guardian must have signed the written informed consent document before study start.
- The patient must be willing and able to comply with all study assessments and procedures.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00007020
United States, Ohio | |
Cincinnati Children's Hospital Medical Center | |
Cincinnati, Ohio, United States, 45229-3039 |
Principal Investigator: | James Heubi, MD | Children's Hospital Medical Center, Cincinnati | |
Principal Investigator: | Kenneth Setchell, PhD | Children's Hospital Medical Center, Cincinnati |
Responsible Party: | Retrophin, Inc. |
ClinicalTrials.gov Identifier: | NCT00007020 History of Changes |
Other Study ID Numbers: |
CAC-91-10-10 CCHMC-91-10-10 ( Other Identifier: Cincinnati Children's Hospital Medical Center ) |
First Posted: | December 7, 2000 Key Record Dates |
Last Update Posted: | May 6, 2015 |
Last Verified: | April 2015 |
Additional relevant MeSH terms:
Adrenoleukodystrophy Cholestasis Peroxisomal Disorders Zellweger Syndrome Refsum Disease, Infantile Refsum Disease Bile Duct Diseases Biliary Tract Diseases Digestive System Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Hereditary Central Nervous System Demyelinating Diseases |
Leukoencephalopathies Demyelinating Diseases Mental Retardation, X-Linked Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolism, Inborn Errors Metabolic Diseases Adrenal Insufficiency Adrenal Gland Diseases Endocrine System Diseases Liver Diseases |